Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- 1 August 2018
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 74 (2) , 218-225
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Journal of Clinical Oncology, 2018
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate CancerEuropean Urology, 2017
- The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancerCancer, 2017
- Treatment strategies for DNA repair-deficient prostate cancerExpert Review of Clinical Pharmacology, 2017
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathEuropean Urology, 2017
- Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate CancerEuropean Urology, 2017
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerNew England Journal of Medicine, 2016
- Familial Risk and Heritability of Cancer Among Twins in Nordic CountriesJAMA, 2016
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerEuropean Urology, 2015